Innocutis Holdings LLC Licenses "Sitavig" from BioAlliance Pharma

CHARLESTON, S.C., March 19, 2014 /PRNewswire/ -- Innocutis Holdings LLC, an innovative pharmaceutical company dedicated to marketing best-in-class branded prescription products in skin-related therapies, is pleased to announce the licensing of Sitavig® (ACYCLOVIR) 50mg Buccal Tablets, from BioAlliance Pharma for the North American markets.  Sitavig represents a breakthrough in the herpes treatment category, which is comprised of over 20 million prescriptions and $4 billion in annual sales within the United States. The Sitavig NDA has been licensed in exchange for a combination of up-front payments, milestones, and royalty payments.  Innocutis is expected to launch Sitavig in third quarter 2014 to the dermatology market through its internal sales and marketing team and will look to sublicense or partner in other specialty markets including women's health and primary care. Innocutis will participate in Bio2014 in San Diego in June 2014 to meet with prospective partners.  Innocutis will be located at booth 1821 at Bio2014.

Photo - http://photos.prnewswire.com/prnh/20140319/PH86097LOGO-a 

Photo - http://photos.prnewswire.com/prnh/20140319/PH86097LOGO-b 

"Sitavig represents a unique opportunity for Innocutis corporately and will change the way clinicians treat herpes labialis.  In order to reach the maximum number of patients in the North American market, with this revolutionary product, Innocutis will pursue sublicensing opportunities in multiple specialty fields while the Innocutis salesforce focuses on dermatology.  As an organization, Innocutis couldn't be more pleased with the partnership that has been developed with BioAlliance Pharma and we look forward to a successful launch of Sitavig in North America," comments Joe Pecora, CEO of Innocutis Holdings LLC. 

Herpes labialis is a widespread condition, affecting up to 58% of the North American population, and has had no treatment breakthroughs in recent years[1].   Sitavig, which maintains multiple patents through 2029, represents a significant breakthrough in the treatment of herpes labialis and is expected to receive widespread patient and clinician acceptance for the treatment of HSV1.

About Innocutis Holdings LLC:

INNOCUTIS is a pharmaceutical company specializing in the development and commercialization of therapies focused on medical treatment of dermatological conditions.  INNOCUTIS' current portfolio of products consists of established branded prescriptions.  At INNOCUTIS we believe our focus on medical dermatology sets us apart as a company that understands the growing needs of the dermatology specialty.  Our commitment is to be "best-in-class" in skin-related therapies, providing clinicians with improved solutions for the management of daily challenges experienced in their practice.  Our "search and development" efforts are designed to identify and acquire late-stage and/or marketed proprietary pharmaceutical products for the treatment of dermatological diseases that have an existing base of safety and efficacy data.

For more information, visit the Innocutis Holdings, LLC web site at www.innocutis.com 

About BioAlliance Pharma

Dedicated to cancer treatments with a focus on resistance targeting and orphan products, BioAlliance Pharma conceives and develops innovative products for orphan or rare diseases. The Company has also successfully developed products based on its innovative muco-adhesive Lauriad® technology both registered in Europe and in the United States.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Innocutis Holdings, LLC and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Innocutis Holdings, LLC to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Innocutis Holdings, LLC is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Innocutis Holdings, LLC
Joe Pecora, CEO
Email

Jonathan Alba, COO
Email
Tel.:  843-965-8333

BioAlliance Pharma SA
Judith Greciet, CEO
Email      

Nicolas Fellmann, CFO
Email
Tel.: +33 1 45 58 76 00

Read more news from Innocutis.

[1] Xu, Fujie; Fujie Xu, MD, PhD; Maya R. Sternberg, PhD; Benny J. Kottiri, PhD; Geraldine M. McQuillan, PhD; Francis K. Lee, PhD; Andre J. Nahmias, MD; Stuart M. Berman, MD, ScM; Lauri E. Markowitz, MD (2006-10-23). "Trends in Herpes Simplex Virus Type 1 and Type 2 Seroprevalence in the United States". JAMA (AMA) 296 (8): 964–73.

SOURCE Innocutis Holdings LLC